Iptakalim Preferentially Decreases Nicotine-induced Hyperlocomotion in Phencyclidine- sensitized Rats: A Potential Dual Action against Nicotine Addiction and Psychosis

키워드

참고문헌 (60)

1. Dalack GW, "Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings", Am J Psychiatry, 155, pp.1490~1501 (1998)
2. Lyon ER, "A review of the effects of nicotine on schizophrenia and antipsychotic medications", Psychiatr Serv, 50, pp.1346~1350 (1999)
3. Gallagher SM, "comparison of smoking cessation treatments for persons with schizophrenia and other serious mental illnesses", J Psychoactive Drugs, 39, pp.487~497 (2007)
4. Lichtermann D, "Incidence of cancer among persons with schizophrenia and their relatives", Arch Gen Psychiatry, 58, pp.573~578 (2001)
5. McEvoy J, "Clozapine decreases smoking in patients with chronic schizophrenia", Biol Psychiatry, 37, pp.550~552 (1995)
6. Wang H, "A new ATP-sensitive potassium channel opener reduces blood pressure and reverses cardiovascular remodeling in experimental hypertension", J Pharmacol Exp Ther, 312, pp.1326~1333 (2005)
7. Wang S, "Effects of systemic administration of iptakalim on extracellular neurotransmitter levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats", Neuropsychopharmacology, 31, pp.933~940 (2006)
8. Hu J, "Iptakalim as a human nicotinic acetylcholine receptor antagonist", J Pharmacol Exp Ther, 316, pp.914~925 (2006)
9. Liu Q, "Iptakalim inhibits nicotine-induced enhancement of extracellular dopamine and glutamate levels in the nucleus accumbens of rats", Brain R, 1085, pp.138~143 (2006)
10. Sun T, "Iptakalim: a potential antipsychotic drug with novel mechanisms?", Eur J Pharmacol, 634, pp.68~76 (2010)
11. Sun T, "Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamineinduced hyperlocomotion: relevance to animal models of antipsychotic drugs", Eur J Pharmacol, 602, pp.334~342 (2009)
12. Li M, "Time course of the antipsychotic effect and the underlying behavioral mechanisms", Neuropsychopharmacology, 32, pp.263~272 (2007)
13. Jentsch JD, "The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia", Neuropsychopharmacology, 20, pp.201~225 (1999)
14. Geyer MA, "Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review", Psychopharmacology, 156, pp.117~154 (2001)
15. Jentsch JD, "Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal corticaldependent cognition in the rat", Neuropsychopharmacology, 17, pp.92~99 (1997)
16. Lee PR, "Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin", Neuropsychopharmacology, 30, pp.1883~1894 (2005)
17. Turgeon SM, "Subchronic phencyclidine exposure potentiates the behavioral and c-Fos response to stressful stimuli in rats", Pharmacol Biochem Behav, 88, pp.73~81 (2007)
18. Perkins KA., "Nicotine self-administration", Nicotine Tob Res, 1(Suppl 2), pp.S133~S137 (1999)
19. Clarke PB, "The effects of nicotine on locomotor activity in non-tolerant and tolerant rats", Br J Pharmacol, 78, pp.329~337 (1983)
20. Li M, "Individual differences in responses to nicotine: tracking changes from adolescence to adulthood", Acta Pharmacol Sin, 30, pp.868~878 (2009)
21. Shoaib M, "Nicotine-induced place preferences following prior nicotine exposure in rats", Psychopharmacology, 113, pp.445~452 (1994)
22. Shram MJ, "Periadolescent and adult rats respond differently in tests measuring the rewarding and aversive effects of nicotine", Psychopharmacology, 186, pp.201~208 (2006)
23. Levin ED, "Acute nicotine interactions with nicotinic and muscarinic antagonists: working and reference memory effects in the 16-arm radial maze", Behav Pharmacol, 8, pp.236~242 (1997)
24. Culm KE, "Recovery of sensorimotor gating without G protein adaptation after repeated D2-like dopamine receptor agonist treatment in rats", J Pharmacol Exp Ther, 308, pp.487~494 (2004)
25. Chen J, "Multiple 'hits' during postnatal and early adulthood periods disrupt the normal development of sensorimotor gating ability in rats", J Psychopharmacol, 25, pp.379~392 (2011)
26. Li M, "Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus", Behav Pharmacol, 20, pp.84~98 (2009)
27. Tenn CC, "Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition", Psychopharmacology, 180, pp.366~376 (2005)
28. Wolf ME., "The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants", Prog Neurobiol, 54, pp.679~720 (1998)
29. Phillips M, "Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration", J Pharmacol Exp Ther, 296, pp.905~913 (2001)
30. Xu X, "Phencyclidine-induced behavioral sensitization", Pharmacol Biochem Behav, 47, pp.603~608 (1994)
31. Swerdlow NR, "Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon", Behav Pharmacol, 11, pp.185~204 (2000)
32. Braff DL, "Sensorimotor gating and schizophrenia. Human and animal model studies", Arch Gen Psychiatry, 47, pp.181~188 (1990)
33. Andreasen JT, "Nicotine and clozapine selectively reverse a PCP-induced deficit of PPI in BALB", cByJ but not NMRI mice: comparison with risperidone, 2006, pp.167, 118~127
34. Spielewoy C, "Strain-specificity in nicotine attenuation of phencyclidine-induced disruption of prepulse inhibition in mice: relevance to smoking in schizophrenia patients", Behav Genet, 34, pp.343~354 (2004)
35. Chaturvedi AK, "Effects of mecamylamine, nicotine, atropine and physostigmine on the phencyclidine-induced behavioral toxicity", Pharmacol Biochem Behav, 20, pp.559~566 (1984)
36. Bevins RA, "Nicotine-conditioned locomotor sensitization in rats: assessment of the US-preexposure effect", Behav Brain Res, 143, pp.65~74 (2003)
37. Laviolette SR, "The motivational valence of nicotine in the rat ventral tegmental area is switched from rewarding to aversive following blockade of the alpha7- subunit-containing nicotinic acetylcholine receptor", Psychopharmacology, 166, pp.306~313 (2003)
38. Acri JB, "Strain and age differences in acoustic startle responses and effects of nicotine in rats", Pharmacol Biochem Behav, 50, pp.191~198 (1995)
39. Faraday MM, "Effects of nicotine and stress on startle amplitude and sensory gating depend on rat strain and sex", Pharmacol Biochem Behav, 62, pp.273~284 (1999)
40. Clarke PB, "Mesolimbic dopamine activation--the key to nicotine reinforcement?", Ciba Found Symp, 152, pp.153~162 (1990)
41. Clarke PB, "Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats", J Pharmacol Exp Ther, 246, pp.701~708 (1988)
42. Bristow LJ, "The glycine", NMDA receptor antagonist, R-(+)-HA-966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK-801) in rodents, 1993, pp.108, 1156~1163
43. Steinpreis RE, "The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of phencyclidine: a microdialysis and behavioral study", Brain Res, 612, pp.263~270 (1993)
44. Nisell M, "Infusion of nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release", Pharmacol Toxicol, 75, pp.348~352 (1994)
45. Hernandez L, "Phencyclidine (PCP) injected in the nucleus accumbens increases extracellular dopamine and serotonin as measured by microdialysis", Life Sci, 42, pp.1713~1723 (1988)
46. norepinephrine release, "J Pharmacol Exp Ther", 1987, 492~497
47. Javitt DC, "Recent advances in the phencyclidine model of schizophrenia", Am J Psychiatry, 148, pp.1301~1308 (1991)
48. Kleijn J, "Direct effect of nicotine on mesolimbic dopamine release in rat nucleus accumbens shell", Neurosci Lett, 493, pp.55~58 (2011)
49. Takahata R, "Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine", Neuropsychopharmacology, 28, pp.1117~1124 (2003)
50. Amitai N, "Repeated phencyclidine administration alters glutamate release and decreases GABA markers in the prefrontal cortex of rats", Neuropharmacology, 62, pp.1422~1431 (2012)
51. Gioanni Y, "Nicotinic receptors in the rat prefrontal cortex: increase in glutamate release and facilitation of mediodorsal thalamo-cortical transmission", Eur J Neurosci, 11, pp.18~30 (1999)
52. Reid MS, "Nicotine stimulation of extracellular glutamate levels in the nucleus accumbens: neuropharmacological characterization", Synapse, 35, pp.129~136 (2000)
53. Hu J, "Iptakalim inhibits nicotinic acetylcholine receptor-mediated currents in dopamine neurons acutely dissociated from rat substantia nigra pars compacta", Neurosci Lett, 403, pp.57~62 (2006)
54. Yang YJ, "Iptakalim alleviated the increase of extracellular dopamine and glutamate induced by 1-methyl-4-phenylpyridinium ion in rat striatum", Neurosci Lett, 404, pp.187~190 (2006)
55. Liu Y, "Iptkalim inhibits cocaine challenge-induced enhancement of dopamine levels in nucleus accumbens and striatum of rats by up-regulating Kir6.1 and Kir6.2 mRNA expression", Acta Pharmacol Sin, 24, pp.527~533 (2003)
56. Miki T, "Roles of KATP channels as metabolic sensors in acute metabolic changes", J Mol Cell Cardiol, 38, pp.917~925 (2005)
57. Takahashi S, "MS-377, a novel selective sigma(1) receptor ligand, reverses phencyclidine-induced release of dopamine and serotonin in rat brain", Eur J Pharmacol, 427, pp.211~219 (2001)
58. Hashimoto K, "Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors", Neuropsychopharmacology, 32, pp.514~521 (2007)
59. Horan B, "The selective sigma(1) receptor agonist, 1-(3,4-dimethoxyphenethyl)-4-(phenylpropyl)piperazine (SA4503), blocks theacquisition of the conditioned place preference response to(-)-nicotine in rats", Eur J Pharmacol, 426, pp.R1~R2 (2001)
60. Nasrallah HA, "Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of schizophrenia", J Clin Psychiatry, 70(Suppl 1), pp.4~46 (2009)

관련 논문AI추천